Payment overview · 2025
General Payments
$747.31
42 reported records · 8 companies
Healthcare provider profile · identity verified
Reid S Christopher, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BESSEMER, AL · NPI 1609978964
Verified facts
What the public records show
CMS Open Payments records show Reid S Christopher, M.D. received $747.31 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $292.91 | 39.2% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.29 | 20.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.42 | 10.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.88 | 10.0% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$49.21 | 6.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.49 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.86 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.25 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $650.50 | 39 |
| Education | $96.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $211.89 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $152.29 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $145.22 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.02 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $74.88 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.53 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 203 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
203 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 1709 | 488 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1287 | 369 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 549 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 455 | 112 |
| Metformin Hcl | Metformin Hcl | 452 | 128 |
| Lisinopril | Lisinopril | 424 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 91 |
| Repatha Sureclick | Evolocumab | 345 | 52 |
| Alprazolam | Alprazolam | 340 | 65 |
| Losartan Potassium | Losartan Potassium | 303 | 92 |
| Gabapentin | Gabapentin | 299 | 95 |
| Spironolactone | Spironolactone | 296 | 77 |
| Ramipril | Ramipril | 277 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 74 |
| Potassium Chloride | Potassium Chloride | 248 | 73 |
| Glimepiride | Glimepiride | 241 | 64 |
| Omeprazole | Omeprazole | 224 | 58 |
| Tramadol Hcl | Tramadol Hcl | 210 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 56 |
| Ozempic | Semaglutide | 203 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 56 |
| Verapamil Er | Verapamil Hcl | 199 | 56 |
| Trazodone Hcl | Trazodone Hcl | 183 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 52 |
| Carvedilol | Carvedilol | 146 | 38 |
| Mounjaro | Tirzepatide | 133 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 39 |
| Colchicine | Colchicine | 128 | 46 |
| Famotidine | Famotidine | 127 | 39 |
| Eliquis | Apixaban | 125 | 24 |
| Clonidine Hcl | Clonidine Hcl | 124 | 38 |
| Sertraline Hcl | Sertraline Hcl | 120 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 34 |
| Simvastatin | Simvastatin | 115 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 21 |
| Clonazepam | Clonazepam | 107 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 30 |
| Lorazepam | Lorazepam | 101 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 43 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 99 | 16 |
| Furosemide | Furosemide | 93 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 29 |
| Nadolol | Nadolol | 88 | 23 |
| Azithromycin | Azithromycin | 87 | 73 |
| Allopurinol | Allopurinol | 73 | 18 |
| Glipizide | Glipizide | 73 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 18 |
| Montelukast Sodium | Montelukast Sodium | 71 | 21 |
| Temazepam | Temazepam | 71 | 19 |
| Pregabalin | Pregabalin | 69 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 61 | 14 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 60 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 13 |
| Levetiracetam | Levetiracetam | 56 | 16 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Ibuprofen | Ibuprofen | 53 | 11 |
| Meloxicam | Meloxicam | 53 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 37 |
| Ondansetron Odt | Ondansetron | 50 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 19 |
| Levemir Flexpen | Insulin Detemir | 49 | 17 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 11 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 12 |
| Metformin Hcl Er | Metformin Hcl | 42 | 19 |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Celecoxib | Celecoxib | 38 | 11 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Atenolol | Atenolol | 37 | 14 |
| Fluconazole | Fluconazole | 37 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 15 |
| Meclizine Hcl | Meclizine Hcl | 37 | 17 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Praluent Pen | Alirocumab | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Valsartan | Valsartan | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 17 |
| Methocarbamol | Methocarbamol | 26 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Naproxen | Naproxen | 25 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 18 |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $747.31 · 42 records | Novo Nordisk Inc | ELIQUIS, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error